As specific ligand-based therapies are likely to provide a better safety profile than global Notch signaling inhibitors, determining the role of Dll1 in TIC generation/function and Notch-mediated chemotherapeutic resistance, may aid in the identification of effective and better-tolerated therapeutics for breast cancer patients. This evidence concerns the gene DLL1 and breast carcinoma.